This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Quarter profit after tax rises 47 percent as revenue slips marginally
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited quarter results to 30 September 2026 show revenue of Rs 185.24 crore, down 0.3 percent year on year. Profit after tax rose 47.3 percent to Rs 11.21 crore. Earnings before interest, tax, depreciation and amortisation margin improved to 9.47 percent from 6.92 percent. In the first half, revenue rose 1.8 percent, profit after tax rose 42.3 percent to Rs 22.64 crore and operating cash flow swung positive to Rs 26.68 crore.
Stronger profit, margins and cash flow support sentiment, but nearly flat revenue and higher inventories temper the near-term appeal.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹185.2 Cr | ₹372.4 Cr | −50.3% |
| Operating profit | ₹14.44 Cr | ₹16.51 Cr | −12.5% |
| Profit after tax | ₹11.21 Cr | ₹15.91 Cr | −29.5% |
| EBITDA margin | 9.2% | 6.0% | +3.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.